Mostrar el registro sencillo del ítem
Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease
dc.contributor.author | Singulani, Monique Patricio | |
dc.contributor.author | Ferreira, Ana Flávia Fernandes | |
dc.contributor.author | Figueroa, Paulina Sepúlveda | |
dc.contributor.author | Cuyul-Vásquez, Iván | |
dc.contributor.author | Talib, Leda Leme | |
dc.contributor.author | Britto, Luiz Roberto | |
dc.contributor.author | Forlenza, Orestes Vicente | |
dc.date.accessioned | 2024-06-19T04:56:21Z | |
dc.date.available | 2024-06-19T04:56:21Z | |
dc.date.issued | 2024 | |
dc.identifier | 10.1016/j.arr.2024.102231 | |
dc.identifier.issn | 15681637 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/11403 | |
dc.description.abstract | The role of lithium as a possible therapeutic strategy for neurodegenerative diseases has generated scientific interest. We systematically reviewed and meta-analyzed pre-clinical and clinical studies that evidenced the neuroprotective effects of lithium in Alzheimer's (AD) and Parkinson's disease (PD). We followed the PRISMA guidelines and performed the systematic literature search using PubMed, EMBASE, Web of Science, and Cochrane Library. A total of 32 articles were identified. Twenty-nine studies were performed in animal models and 3 studies were performed on human samples of AD. A total of 17 preclinical studies were included in the meta-analysis. Our analysis showed that lithium treatment has neuroprotective effects in diseases. Lithium treatment reduced amyloid-β and tau levels and significantly improved cognitive behavior in animal models of AD. Lithium increased the tyrosine hydroxylase levels and improved motor behavior in the PD model. Despite fewer clinical studies on these aspects, we evidenced the positive effects of lithium in AD patients. This study lends further support to the idea of lithium's therapeutic potential in neurodegenerative diseases. © 2024 Elsevier B.V. | es_ES |
dc.description.sponsorship | Fondecyt de Iniciación; Instituto Nacional de Biomarcadores em Neuropsiquiatria; Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP, (2018/07366-4, 2020/02109-3, 2021/06378-1); Fundação de Amparo à Pesquisa do Estado de São Paulo, FAPESP; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES, (88887.514714/2020-00); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES; Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, (167176/2023-4, 2014/50873-3, 303006/2018-8, 465412/2014-9); Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq; Agencia Nacional de Investigación y Desarrollo, ANID, (11240905); Agencia Nacional de Investigación y Desarrollo, ANID | es_ES |
dc.language.iso | en | es_ES |
dc.publisher | Elsevier Ireland Ltd | es_ES |
dc.subject | Alzheimer's disease | es_ES |
dc.subject | Lithium | es_ES |
dc.subject | neuroprotection | es_ES |
dc.subject | Parkinson's disease | es_ES |
dc.subject | prevention and treatment | es_ES |
dc.title | Lithium and disease modification: A systematic review and meta-analysis in Alzheimer's and Parkinson's disease | es_ES |
dc.type | Article | es_ES |